Personalized TCR-T therapies
for exceptional outcomes.
Welcome To APT Oncology
APT Oncology is a groundbreaking joint venture between AmplifyBio and Pathfinder Oncology, dedicated to advancing personalized TCR-T therapies for oncology patients. By leveraging AmplifyBio’s clinically validated TCR therapy platform, acquired from PACT Pharma, and Pathfinder Oncology’s immuno-oncology expertise and patient-centric approach, APT Oncology aims to create novel, patient-specific T-cell therapies for advanced solid tumors.
Company Overview
- Expertise in TCR discovery and manufacturing: AmplifyBio brings its TCR discovery and validation expertise, driven by a clinically validated, non-viral editing approach for TCR-T cell manufacturing.
- Patient-centric approach: Pathfinder can combine expertise in immuno-oncology and personalized patient plans with Amplify’s discovery and manufacturing platform to advance a customized solution for patients.
- Accelerated access to immunotherapies: APT Oncology is committed to rapidly advancing TCR-based therapies from discovery to clinical application, ensuring patients receive the most promising treatments.
We are committed to expanding access to innovative immunotherapies, ensuring patients get the best treatments. Join us in transforming cancer care and bringing hope worldwide.
Latest News
Have additional questions?
We’re here to help. Let’s talk.